Hengrui gains China approval for ANGPTL3 antibody in rare cholesterol disorder
Jiangsu Hengrui (600276.SS) subsidiary Suncadia won China NMPA approval for ANGPTL3 antibody SHR-1918 in HoFH patients aged 12+. Launch timing, pricing and NRDL status remain ahead.
Jiangsu Hengrui Pharmaceuticals has secured Chinese approval for its ANGPTL3 antibody, developed as SHR-1918, for adults and adolescents aged 12 and older with homozygous familial hypercholesterolemia (HoFH), a rare inherited disorder that causes severely elevated LDL cholesterol.
In its announcement dated November 12, Hengrui said subsidiary Beijing Suncadia Pharmaceuticals received the approval. The subcutaneous product can be used with a low-fat diet and other lipid-lowering medicines to reduce LDL cholesterol. The approved indication is specific to HoFH.
The filing lists a 300 mg/2 mL prefilled auto-injector. That is the presentation strength; the announcement does not establish the prescribed dosing regimen. It identifies the supporting study as SHR-1918-301, a randomized, double-blind, placebo-controlled Phase 3 trial in HoFH patients aged at least 12, presented at the 2026 European Society of Cardiology congress.
HoFH involves absent or severely impaired LDL-receptor function. Hengrui's disclosure explains that this limits the effect of therapies that depend on that pathway, providing the rationale for an alternative lipid-lowering approach.
For industry readers, the immediate change is a move from clinical development to an approved, narrowly defined commercial indication. The announcement does not specify launch timing, price or reimbursement arrangements. Those disclosures will be needed to assess how the approval translates into access and sales.
Related on China Pharma Desk: Ribo’s EU filing for dual-target lipid siRNA SR122 (ApoC3/PCSK9) · China targets hospital formulary barriers for Class 1 innovative drugs